Latest News from: University of California San Diego Health

Add to Favorites Subscribe Share
Go to Advanced Search

Showing results

110 of 1459
Embargo will expire:
18-Dec-2018 1:00 PM EST
Released to reporters:
12-Dec-2018 12:05 PM EST

EMBARGOED

A reporter's PressPass is required to access this story until the embargo expires on 18-Dec-2018 1:00 PM EST

The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application.
If you have not yet registered, please do so. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

cheresh_david_UCSDHealth.jpg

Article ID: 705131

UC San Diego Researcher Gets $4 Million NCI Award to Study Cancer Drug Resistance, Spread

University of California San Diego Health

David Cheresh, Distinguished Professor at University of California San Diego School of Medicine, received $4.2 million National Cancer Institute Outstanding Investigator Award to continue his research into cancer’s ability to overcome stress, gain drug resistance and metastasize.

Released:
7-Dec-2018 2:05 PM EST

Article ID: 705087

Targeted Cognitive Training Benefits Patients with Severe Schizophrenia

University of California San Diego Health

Researchers find that patients with severe, refractory schizophrenia benefit from targeted cognitive therapy, improving auditory and verbal outcomes and the way they process information.

Released:
6-Dec-2018 4:05 PM EST

Education

winzler_researchteam_UCSDHealth.jpg
  • Embargo expired:
    6-Dec-2018 2:00 PM EST

Article ID: 704793

One Million Mosquitoes and 500,000 Tests Later, New Buzz about a Malaria Prevention Drug

University of California San Diego Health

Researchers spent two years testing chemical compounds for their ability to inhibit the malaria parasite at an earlier stage in its lifecycle than most current drugs, revealing a new set of chemical starting points for the first drugs to prevent malaria instead of just treating the symptoms.

Released:
3-Dec-2018 1:05 PM EST
CoverArt_ChemoresistantCell.jpg

Article ID: 704966

UC San Diego Researchers Develop Sensors to Detect and Measure Cancer’s Ability to Spread

University of California San Diego Health

University of California San Diego School of Medicine researchers engineered sensors to detect and measure the metastatic potential of single cancer cells. Metastasis is attributed as the leading cause of death in people with cancer.

Released:
5-Dec-2018 11:05 AM EST
ucsd_med_center_UCSDHealth.jpg

Article ID: 704926

UC San Diego Medical Center Named by Leapfrog as “2018 Top Teaching Hospital”

University of California San Diego Health

UC San Diego Medical Center in Hillcrest was named a Top Teaching Hospital by The Leapfrog Group. The award is widely acknowledged as one of the most competitive honors that a U.S. hospital can receive.

Released:
4-Dec-2018 4:05 PM EST
zanetti_B_cells_graphic.png

Article ID: 704859

New Cancer Immunotherapy Approach Turns Immune Cells into Tiny Anti-Tumor Drug Factories

University of California San Diego Health

In lab and mouse experiments, UC San Diego School of Medicine researchers developed a method to leverage B cells to manufacture and secrete tumor-suppressing microRNAs.

Released:
4-Dec-2018 11:05 AM EST
ball_edward_UCSDHealth.jpg

Article ID: 704773

UC San Diego Health is First in San Diego to offer CAR T-cell Therapy for Some Cancers

University of California San Diego Health

Following the Food and Drug Administration’s approval of chimeric antigen receptor (CAR) T-cell therapies for the treatment of certain types of non-Hodgkin lymphomas, UC San Diego Health was the first medical center in San Diego to be certified to offer this type of immunotherapy outside of a clinical trial.

Released:
3-Dec-2018 11:05 AM EST
cohen_ezra_UCSDHealth.jpg
  • Embargo expired:
    30-Nov-2018 6:30 PM EST

Article ID: 704737

Immunotherapy Better than Chemotherapy for Subtype of Head and Neck Cancer

University of California San Diego Health

A randomized clinical trial involving 97 medical centers in 20 countries, including Moores Cancer Center at UC San Diego Health, found that treating patients with head and neck cancer with the immunotherapy drug pembrolizumab is more effective and less toxic than standard chemotherapy.

Released:
30-Nov-2018 4:05 PM EST
good_to_go_UCSDHealth.jpg

Article ID: 704722

New UC San Diego Campaign Promotes Sexual Health — and has a Quick Test to Prove It

University of California San Diego Health

New UC San Diego campaign promotes sexual health and has a quick test to prove it. “Good to Go” offers combined testing for HIV and five sexually transmitted diseases, providing some results in as little as 60 seconds and access to free treatment, if needed. Updated clinic opening Dec. 10.

Released:
30-Nov-2018 3:05 PM EST

Showing results

110 of 1459

Chat now!